Barriers to access of precision guided therapies for children with high‐risk cancer
This study provides insight to the challenges faced when seeking access to novel therapies for paediatric oncology patients. There is a clear need for improved communication, streamlining processes and increased resources to facilitate access to novel agents. Further resource development is necessary to address these complexities in accessing novel therapy agents to ultimately ensure equitable and timely access.
Authors
- Carolyn Mazariego (ORCID: https://orcid.org/0000-0003-3965-4960)
- Claire Elizabeth Wakefield (ORCID: https://orcid.org/0000-0001-7704-7067)
- Kate Hetherington (ORCID: https://orcid.org/0000-0002-5457-5462)
- David S. Ziegler (ORCID: https://orcid.org/0000-0001-7451-7916)
- Natalie Taylor (ORCID: https://orcid.org/0000-0002-0280-0883)
- Rebecca Daly (ORCID: https://orcid.org/0000-0003-1096-0526)
- Lauren Kelada (ORCID: https://orcid.org/0000-0001-9428-8807)
- Brittany C. McGill (ORCID: https://orcid.org/0000-0002-2134-2988)
- Skye McKay
Institutions
- UNSW Sydney (AU)
- Children's Cancer Institute Australia (AU)
- Sydney Children's Hospital (AU)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1002/pbc.31147
- Citations
- 3
- Primary Topic
- Childhood Cancer Survivors' Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.33
Funders
- Children's Medical Research
- Cancer Institute NSW
- University of New South Wales
- New South Wales Government
- National Health and Medical Research Council